Cargando…
626. The Efficacy and Safety of Maintenance with Doravirine Plus Two NRTIs after Initial Suppression in Adults with HIV-1 in the DRIVE-FORWARD Clinical Trial: Results from the Study Extension through 192 Weeks
BACKGROUND: DRIVE-FORWARD is a phase 3 trial with a completed double-blind period comparing doravirine (DOR) 100 mg with ritonavir-boosted darunavir (DRV/r) 800/100 mg, both administered with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs; tenofovir and emtricitabine, or abacavir and lami...
Autores principales: | Cahn, Pedro, Molina, Jean-michel, Lombaard, Johan, Squires, Kathleen, Kumar, Sushma, Wan, Hong, Teal, Valerie, Asante-Appiah, Ernest, Sklar, Peter, Martin, Elizabeth A, Lahoulou, Rima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644615/ http://dx.doi.org/10.1093/ofid/ofab466.824 |
Ejemplares similares
-
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020) -
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates
por: Asante-Appiah, Ernest, et al.
Publicado: (2021) -
The clinical development of NRTIs — cautionary tales
por: Cooper, D
Publicado: (2010) -
LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Kumar, Princy, et al.
Publicado: (2018) -
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Johnson, Margaret, et al.
Publicado: (2019)